Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F25%3A00082274" target="_blank" >RIV/65269705:_____/25:00082274 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/25:00143855
Result on the web
<a href="https://ashpublications.org/bloodadvances/article/9/13/3336/535732/Gastrointestinal-toxicity-of-gemtuzumab-ozogamicin" target="_blank" >https://ashpublications.org/bloodadvances/article/9/13/3336/535732/Gastrointestinal-toxicity-of-gemtuzumab-ozogamicin</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/bloodadvances.2024014570" target="_blank" >10.1182/bloodadvances.2024014570</a>
Alternative languages
Result language
angličtina
Original language name
Gastrointestinal toxicity of gemtuzumab ozogamicin: real-life data from the AMLCG, SAL, and CELL study groups
Original language description
The CD33-directed antibody-drug-conjugate "gemtuzumab ozogamicin" (GO) in combination with the 7+3 standard regimen is currently approved for the treatment of CD33+ acute myeloid leukemia (AML). Although the pivotal ALFA-0701 study did not show a significantly increased toxicity using 7+3 + GO compared with 7+3,1 a slightly higher rate of severe gastrointestinal (GI) toxicity was reported (16% vs 10%), and additional evidence of GO-associated GI toxicity was published.2,3 We observed several cases of severe GI toxicity and therefore analyzed patients treated with GO in a real-world setting.Our findings are based on a single-center analysis of patients treated at the University Hospital Munich and a multicenter analysis from 32 hospitals of the German SAL (Study Alliance Leukemia), the AMLCG (AML Cooperative Group), the CELL (Czech Leukemia Study Group), and other university hospitals of Germany. For further information about the methods used in our analyses, refer to supplemental Methods.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Advances
ISSN
2473-9529
e-ISSN
2473-9537
Volume of the periodical
9
Issue of the periodical within the volume
13
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
4
Pages from-to
3336-3339
UT code for WoS article
001533729300007
EID of the result in the Scopus database
2-s2.0-105009615117